Third, increased CRP might reduce nitric oxide bioavailability via decreasing urinary excretion of cyclic guanosine monophosphate and activating NADPH oxidase, which could aggravate hypertension and thus MetS [34, 35]. This evidence concerns the gene FMO5 and hypertensive disorder.